The rapid development in treatment options for patients with chronic lymphocytic leukemia (CLL) in parallel with a much more detailed understanding of the underlying pathogenesis has warranted the development of novel prognostic indices for patients with CLL to replace the clinical staging systems developed by Rai and Binet 40 years ago. 1, 2 Bahlo and colleagues from an international consortium have developed a new international prognostic index for patients with chronic lymphocytic leukemia (CLL-IPI) based on a combination of molecular and clinical baseline characteristics for patients with CLL.
3,4 The impact of previously proposed prognostic models has been limited due to omission of molecular characteristics, 5 inclusion of parameters not widely used, 6 or restriction to cytogenetic findings.
7
With an initial assessment of 27 baseline markers in patients enrolled in 8 clinical trials, they have established the CLL-IPI prognostic model based on 5 parameters becoming widely available: TP53 aberrations (including del(17p) and TP53 mutation), IGHV mutational status, b(2)microglobulin level, clinical stage and age. The model was validated in 2 external cohorts including patients followed from time of diagnosis. The establishment of a robust and widely accepted international prognostic index in CLL to guide treatment decisions and assess the composition of in trial populations is an important and valuable tool.
8 The CLL-IPI was developed based on participants in clinical trials before the era of chemoimmunotherapy, with only 571 out of 3725 patients receiving chemoimmunotherapy as first-line treatment. The included patients were younger (median age, 61 years) and mainly physically fit (96% ECOG performance status [PS] 0-1) compared with the general population of newly diagnosed patients with CLL. 4 Thus, application and validation of the CLL-IPI in a population-based cohort of patients with newly diagnosed CLL in the current era of chemoimmunotherapy is warranted prior to broader implementation.
Here, we present data from the prospective Danish National CLL Registry, which is a nationwide, mandatory registry including and prospectively following all consecutive patients diagnosed with CLL in Denmark since 2008 to estimate time to event (TTE; treatment or death) and overall survival (OS) according to the 4 CLL-IPI risk groups. The median observation time was 3.2 years, and the median survival was not reached. For patients excluded from the analysis due to $1 missing CLL-IPI variables, 898 (61%) were male, 71 years was the median age, 335 (24%) had Binet stage B or C, 1356 (93%) had PS 0-1, the 3-year OS was 80%, and the 3-year eventfree survival was 70%.
For our analyses, the 4 different risk categories proposed by Bahlo et al 3 predicted significantly different TTE and OS (P , .001) for each of the 4 risk categories (Figure 1) . Thus, the robustness of the CLL-IPI index in an unselected cohort of patients with newly diagnosed patients CLL in the era of chemoimmunotherapy could be confirmed.
As single-agent targeted treatment and combinations of chemotherapy-and non-chemotherapy-based options are evolving, the CLL-IPI may be used to identify at the time of diagnosis CLL patients who will likely not benefit from conventional chemoimmunotherapy, as proposed by Bahlo et al. Our data presented here provide the basis for external validation of the CLL-IPI in a populationbased cohort exposed to chemoimmunotherapy. As such, the CLL-IPI could prove a critical step in predicting the time from diagnosis to a need for treatment and help guide therapeutic decision making in the era of novel targeted treatment options for CLL. We encourage all centers caring for patients with CLL to integrate the 5 parameters as part of their routine diagnostic workup and to report the CLL-IPI risk categories for patients in clinical trials.
